Bisphosphonates don’t cut risk of breast cancer

Three to four years of therapy with the bisphosphonates alendronate and zoledronic acid, taken at doses used to treat osteoporosis, did not decrease the risk of incident breast cancer in...

Field of Interest: Oncology
Type: News Item

Bisphosphonates don’t cut risk of breast cancer

Three to four years of therapy with the bisphosphonates alendronate and zoledronic acid, taken at doses used to treat osteoporosis, did not decrease the risk of incident breast cancer in...

Field of Interest: Pulmonology
Type: News Item

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness